--- title: "Pre-market hot trades in US stocks: GeoVax Labs up 10.76% in pre-market; Banco Santander SA-Spon up 3.90% in pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/293920261.md" description: "GeoVax Labs pre-market up 10.76%; Banco Santander SA-Spon pre-market up 3.90%; Lion Group Holding pre-market up 122.95%; Matinas BioPharma pre-market up 74.36%; First Tracks Biotherapeutics pre-market up 41.72%" datetime: "2026-07-27T10:57:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293920261.md) - [en](https://longbridge.com/en/news/293920261.md) - [zh-HK](https://longbridge.com/zh-HK/news/293920261.md) generator: "portal-rs" --- # Pre-market hot trades in US stocks: GeoVax Labs up 10.76% in pre-market; Banco Santander SA-Spon up 3.90% in pre-market **Pre-market Hot Trades in US Stocks** GeoVax Labs, up 10.76% in pre-market trading, has no significant recent news. The trading is active with clear capital flow, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. Banco Santander SA-Spon is up 3.90% in pre-market trading. Based on recent key news: 1. On July 24, Banco Santander SA-Spon executive Francisco Javier Garcia-Carranza Benjumea sold 319,686 shares at a price of €11.95 per share. This news may trigger market attention on the company's internal movements, leading to stock price fluctuations. 2. On July 24, Getnet, a subsidiary of Banco Santander SA-Spon, began accepting WeChat Pay at POS terminals in Spain, aiming to attract Chinese and other Asian tourists. This initiative is expected to increase payment convenience for merchants, boost tourism consumption, and enhance company revenue. 3. On July 24, Banco Santander SA-Spon announced its performance for the first half of 2026, showing double-digit profit growth, improved efficiency, strong capital generation, and asset quality and liquidity ratios far exceeding regulatory requirements. Strategic digital transformation and diversification continue to drive value growth, helping the group achieve its 2026 goals. The recovery of the tourism industry and enhanced payment convenience contribute to strong performance. **Top Gainers in Pre-market US Stocks** Lion Group Holding is up 122.95% in pre-market trading. Based on recent key news: 1. On July 23, HRT Financial sold 34,989 shares of Lion Group Holding at prices of $1.46 and $1.36, reducing its holdings to 63,695 shares. This move may trigger market attention on the company's stock price, leading to fluctuations. 2. On July 24, Spark's AI analyst rated Lion Group Holding as neutral, pointing out the company's weak financial performance, ongoing losses, and unstable revenue leading to a bearish technical outlook. Despite the stock being oversold, it remains below key moving averages. 3. On July 24, Lion Group Holding's year-to-date stock performance has declined by 94.16%, with an average trading volume of 877,862, market sentiment signals a sell, and the market capitalization is $725,900. Market sentiment is bearish, and technicals are under pressure. Matinas BioPharma is up 74.36% in pre-market trading. Based on recent key news: 1. On July 23, Matinas BioPharma announced the termination of its market sales agreement with BTIG. This agreement allowed the company to issue up to $50 million in common stock through the market. The termination of the agreement results in the loss of an important financing channel, which may affect its future fundraising capabilities. 2. On July 24, after BTIG terminated the sales agreement, Matinas BioPharma incurred no termination fees or expenses. This move may be interpreted by the market as an enhancement of the company's financial stability, driving the stock price up On July 25th, analyst Spark rated Matinas Biopharma as neutral, mainly due to the company's weak financial performance and negative signals from the technical perspective. Nevertheless, the market reacted positively to the company's strategic changes, leading to a significant increase in stock price. The biopharmaceutical industry has been quite volatile recently and requires attention. First Tracks Biotherapeutics rose 41.72% in pre-market trading, with no significant news recently. The trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation ### Related Stocks - [GOVX.US](https://longbridge.com/en/quote/GOVX.US.md) - [SAN.US](https://longbridge.com/en/quote/SAN.US.md) - [LGHL.US](https://longbridge.com/en/quote/LGHL.US.md) - [MTNB.US](https://longbridge.com/en/quote/MTNB.US.md) - [TRAX.US](https://longbridge.com/en/quote/TRAX.US.md) ## Related News & Research - [Santander completes EUR 5.03 billion buyback, set to cut share capital 3.08%](https://longbridge.com/en/news/296645313.md) - [With Webster in hand, Santander says it's poised for growth](https://longbridge.com/en/news/296520178.md) - [Santander completes Webster Financial acquisition, issues 329,846,438 new shares at EUR 10.79 each](https://longbridge.com/en/news/296445161.md) - [Diversify Advisory Services LLC Buys New Holdings in Regeneron Pharmaceuticals, Inc. $REGN](https://longbridge.com/en/news/296585791.md) - [Santander plans exchange offers to buy remaining minority stake in Santander Brasil](https://longbridge.com/en/news/295981286.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**